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A B S T R A C T  
Objective: To evaluate the effect of losartan in comparison with pioglitazone on lipid profile in a type 2 diabetic rat 
mode. 
Materials and Methods: This case control study was conducted in Postgraduate Medical Institute (PGMI), Lahore from 
June to August 2011. Forty-five Sprague-Dawley rats of 5 weeks of age were randomized into three groups. All the rats 
were fed a high fat and sucrose diet. Pioglitazone or Losartan were given along with this diet to the rats in groups HFD-
PIO and HFD-LOS respectively, while group HFD was kept as control. At the end of 12 weeks, serum samples were 
obtained from all the animals and total cholesterol, HDL-cholesterol and triglyceride levels were obtained using kit 
method. LDL-cholesterol was determined using the Friedewald formula. 
Results: At the end of study period, lipid profile parameters were statistically improved between HFD-PIO and the 
control HFD group. The difference in the lipid profile parameters between the HFD-LOS and the control HFD group as 
well as between the HFD-PIO and HFD-LOS groups was not significant. 
Conclusion: The ARB losartan has a small but insignificant effect on lipid profile. 
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I n t r o d u c t i o n  
 
Diabetes mellitus is one of the leading chronic diseases in 
almost every country1, is characterized by increased 
blood glucose levels. Its associated complications 
including dyslipidemia lead to increased morbidity and 
mortality. Patients with adverse lipid profile including 
hypertriglycedemia, high levels of low density lipoproteins 
(LDL) and low levels of high density lipoproteins (HDL) 
are at high risk of cardiovascular disease.2 Many patients 
with type 2 diabetes have an abnormal lipid profile 
characterized by increased triglycerides and decreased 
high density lipoproteins HDL-C.3 Studies have shown 
that a high fat plus high carbohydrate diet play a major 
role in the pathogenesis of type 2 diabetes mellitus and 
dyslipidemia.4 A diet that contains a high percentage of 
saturated fatty acids and refined carbohydrates in 
combination is an unhealthy diet that may lead to insulin 
resistance, type 2 diabetes mellitus, dyslipidemia and 
various other features of the metabolic syndrome. Such 
ORIGINAL ARTICLE 
                            37 JIMDC  2018  37 
diets have been used to induce diabetes and dyslipidemia 
in animal models.5 
It is well known that cholesterol homeostasis is 
fundamental for appropriate insulin secretory function of β 
cells. Excessive cholesterol accumulation in β cells, when 
exposed to chronically increased levels of free fatty acids 
(for example in obesity or due to high fat diet), may cause 
lipotoxicity and reduce insulin secretion, causing β cell 
dysfunction & decreased β cell mass.6 
Dyslipidemia has been seen to be associated with 
dysfunction of pancreatic β cells and this is particularly 
evident in people with elevated total cholesterol (TC) and 
LDL-C levels.7 Thiazolidinediones (Glitazones) are a 
group of drugs used for treatment of type 2 diabetes 
which have shown to preserve beta cell function by 
protecting beta-cell from lipotoxicity.8 Glitazones are 
selective agonists of peroxisome proliferator activated 
receptor gamma (PPAR𝛾), a nuclear receptor which is 
most highly expressed in adipose tissue and controls the 
transcription and translation of a variety of genes involved 
in glucose and lipid metabolism.9 PPAR-γ is currently 
regarded as a therapeutic target in the metabolic 
syndrome.10 Pioglitazone, one of the major glitazones 
being used in the treatment in T2DM has shown to 
improve lipid profile including decrease in triglycerides 
and low-density lipoprotein (LDL), increase in high-density 
lipoprotein (HDL) and decrease in serum fatty acids.11 
Renin-angiotensin-aldosterone system has been linked 
with obesity-related hypertension and it is also involved in 
the association among obesity, metabolic syndrome, 
dyslipidemia, insulin resistance, chronic kidney disease, 
and hypertension.12 ACE Inhibitors have shown positive 
effects on the lipid profiles in children with the metabolic 
syndrome. Results in the study showed statistically 
significant decrease in LDL & triglyceride levels and 
significant increase in HDL levels.13 Now several ARBs 
(Angiotensin Receptor Blockers) including Telmisartan, 
Irbesartan and Losartan have shown to possess PPAR-γ 
agonist activity. Beneficial effects of PPAR-γ agonist 
activity on improving insulin sensitivity have been 
mentioned. This provides a strategic rationale and 
pharmacological platform for the use of dual ARB/PPAR-γ 
agonists to target the metabolic syndrome and its 
cardiovascular sequelae.10 
This provides the basis for the present study to observe 
effects, if any, of a dual ARB/PPAR-γ agonist losartan on 
lipid profile in a rat model of type 2 diabetes mellitus. 
M a t e r i a l s  a n d  M e t h o d s  
This randomized control trial was conducted at 
Postgraduate Medical Institute (PGMI), Lahore from June 
2018 to August 2018. The sample size was estimated by 
using 5% level of significance and 80% power of test with 
expected frequency of diabetes mellitus; 36, 57 and 94 
percent in glitazones, angiotensin receptor blockers and 
control groups respectively.15,16 The estimated sample 
size was 13 in each group (total 39). It was increased to 
15 in each group (total 45) to increase the accuracy of the 
results and to decrease the margin of error. Sprague-
Dawley rats of 4 weeks of age were purchased from the 
University of Veterinary & Animal Sciences, Lahore and 
kept in the animal house of PGMI in iron cages under 
hygienic conditions. Room temperature was maintained at 
25 + 2C under natural day/night cycle with free access to 
rat chow and water. They were allowed one week to 
acclimatize. From 5 weeks of age rats were fed on high 
fat diet containing 30% beef fat and 10% sucrose.14 
Animals were divided randomly into 3 groups of 15 
animals each. All three groups were fed high fat and 
sucrose diet throughout study period of 12 weeks. First 
group was given distilled water daily orally as a single 
morning dose and labeled as HFD (high fat diet) group. 
Second group was given pioglitazone in dose of 10mg/kg 
body weigh daily orally as a single morning dose for 12 
weeks and labeled as HFD-PIO group.15 Third group was 
given losartan in dose of 10mg/kg body weight daily orally 
as a single morning dose for 12 weeks and labeled as 
HFD-LOS group.1 Drugs Pioglitazone and losartan were 
obtained from Mass Pharmaceuticals. Each rat was 
weighed initially and after every week. Fasting blood 
glucose level was measured every week using a 
glucometer (AccuChek) using a drop of blood obtained 
from the tail vein. After 12 weeks rats were kept on 12 
hour fast and blood was collected by cardiac puncture. 
Samples were then centrifuged at room temperature at 
3000-4000 rpm for 5 minutes. Serum was stored at –20°C 
until analyzed for lipid profile. Total cholesterol, HDL-
cholesterol and triglyceride levels were obtained using 
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calorimetric kit methods. LDL-cholesterol was determined 
using the Friedewald formula:17 
 LDL = Total Cholesterol – HDL Cholesterol – 
Triglycerides/5.  
The data was entered and analyzed using SPSS 17.0. 
Mean ± SD was analyzed for quantitative variables like 
body weight, fasting blood glucose levels and lipid profile. 
One-way ANOVA was applied to compare the variables 
among the groups. Bonferroni’s post-test was applied to 
see whether variances were significantly different.  
R e s u l t s  
Mean fasting blood glucose level of animals at the start of 
study was 92±9, 87±7 and 91±7 mg/dl in group HFD, 
HFD-PIO and HFD-LOS respectively. Fasting blood 
glucose level increased in all groups over the study 
period. At 12 week fasting blood glucose level was 
significantly less in HFD-PIO and HFD-LOS group as 
compared to that of HFD group. Difference between HFD-
PIO and HFD-LOS group was not significant (Table 1). At 
12 weeks, mean serum cholesterol, LDL and triglyceride 
levels were higher and mean HDL level was lower in the 
control HFD group as compared to the HFD-PIO and 
HFD-LOS groups (Table 2). The mean serum cholesterol, 
LDL and triglyceride levels were higher and mean HDL 
level was lower in the HFD-LOS group as compared to 
the HFD-PIO group (Table 2). Total cholesterol and LDL 
levels were found to be significantly less in the HFD-PIO 
group as compared to that of HFD group. Triglyceride 
levels were also significantly less. HDL levels showed no 
significance between HFD-PIO and the control HFD group 
(Table 2). There was no statistical difference in any of the 
lipid parameters between HFD-LOS and the control HFD 
group as well as between the HFD-PIO and HFD-LOS 
groups (Table 2). 
D i s c u s s i o n  
In the present study, the effect of losartan on lipid profile 
was evaluated on rats fed a high fat plus sucrose diet, in 
comparison with pioglitazone. For this purpose, 45 
Sprague-Dawley rats of 5 weeks of age were randomized 
into three groups. All the rats in each group were fed a 
high fat and sucrose diet. Such an animal model is the 
best model to study the human metabolic syndrome. 
Numerous studies have shown that a diet rich in saturated 
fatty acids and refined carbohydrates increases the risk of 
developing the metabolic syndrome characterized by 
dyslipidemia, impaired glucose tolerance, insulin 
resistance and hypertension.5 
Pioglitazone and losartan were given along with this diet 
to the rats in group HFD-PIO and HFD-LOS respectively, 
while group HFD was kept as control. At the end of 12 
weeks, serum samples were obtained from all the animals 
and total cholesterol, HDL-cholesterol and triglyceride 
levels were obtained using kit method. LDL-cholesterol 
was determined using the Friedewald formula. At 12 
weeks, mean serum cholesterol, LDL and triglyceride 
levels were higher and mean HDL level was lower in the 
control HFD group as compared to the HFD-PIO and 
HFD-LOS groups. Total cholesterol, triglyceride and LDL 
levels were found to be significantly less in the group of 
rats fed pioglitazone along with the high fat diet (HFD-
PIO), as compared to the rats fed high fat diet alone 
(HFD).The rise in serum cholesterol, LDL & triglyceride 
levels and decrease in HDL cholesterol in rats fed on a 
high fat diet are consistent with effects of development of 
the metabolic syndrome in such animals.5 Similarly, 
findings are also seen in humans fed a high fed diet.18 
The decrease in triglycerides, total cholesterol and LDL 
cholesterol by pioglitazone is also consistent with several 
studies on this drug. Thiazolidinediones, especially 
pioglitazone, have shown to have favorable effects on 
plasma lipids. Pioglitazone has shown in several studies 
to reduce triglyceride levels, total cholesterol and LDL 
cholesterol.19  
Increase in HDL cholesterol however was not significant 
in the present study. The mechanisms by which 
pioglitazone produces these effects are highly complex 
and may involve anti-oxidant, anti-thrombotic, anti-
inflammatory, anti-apoptotic and anti-infective properties, 
as well as effects on endothelial function and repair. 
These may be associated with their effects on peroxisome 
proliferator-activated receptor-gamma (PPARγ) 
receptors.20 The present study showed a small but 
insignificant decrease in triglycerides, total cholesterol 
and LDL in rats fed a high fat diet plus losartan as 
compared to the rats fed on a high fat diet alone. HDL 
cholesterol also showed no significant change. Studies 
have shown variation in effects by different ARBs on lipid 
profile.21 It may also have been because the present 
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study was a preventive study in which some of the rats 
developed diabetes and some did not when fed on a high 
fat diet alone (HFD) or with pioglitazone (HFD-PIO) or 
losartan (HFD-LOS). 
 
Table 1: Body weight, fasting blood glucose and insulin levels of HFD fed rats at end of 12 week study period 
(n=45) 
Groups Body Weight  
(g) 
p-value* Fasting Blood 
Glucose (mg/dl) 
p-value* Serum Insulin 
(µIU/ml) 
p-value* 
HFD (mean±SD) 382 ± 48 --- 152 ± 12 ---- 23.20 ± 5.52 ---- 
HFD-PIO (mean±SD) 345 ± 45 ≤ 0.05 123 ± 17 ≤ 0.001 12.07 ± 6.82 ≤ 0.001 
HFD-LOS (mean±SD) 342 ± 38 ≤ 0.05 132±17 ≤ 0.001 14.13 ± 8.83 ≤ 0.01 
Table 2:  Lipid profile of HFD fed rats at end of 12 week study period (n=45) 
Groups Total 
Cholesterol 
p-value* Triglycerides p-
value* 
LDL p-
value* 
HDL p-
value* 
HFD  (mean 
± SD) 
138.5±7.97 ___ 169.2±9.93 ____ 84.1 ± 
7.17 
____ 20.6 ± 3.22 _____ 
HFD-PIO 
(mean ± SD) 
125.1±14.25  < 0.01 157.1 ± 16.35  <0.05 69.3 ± 
13.94 
< 0.01 24.4 ± 3.60 > 0.05 
HFD-LOS 
(mean ± SD) 
131.3±15.18 > 0.05 162.3 ± 17.44 >0.05 76.3 ± 
14.59 
> 0.05 22.6 ± 3.94 >0.05 
There was also no significant difference in effects on lipid 
profile parameters between rats fed on a high fat diet plus 
losartan and rats fed a high diet plus pioglitazone. 
C o n c l u s i o n  
The topical Nifedipine is more effective in relieving the 
pain and healing as compared to oral form in CAF. 
Further research work on large scale is recommended to 
evaluate the oral and topical forms of Nifedipine for the 
treatment of CAF. 
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